Title: Fondaparinux Sodium
CAS Registry Number: 114870-03-0
CAS Name: Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(1®4)-O-b-D-glucopyranuronosyl-(1®4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(1®4)-O-2-O-sulfo-a-L-idopyranuronosyl(1®4)-2-deoxy-2-(sulfoamino)-a-D-glucopyranoside 6-(hydrogen sulfate) decasodium salt
Additional Names: fondaparin sodium; SR-90107A; Org-31540
Manufacturers' Codes: IC-851589
Trademarks: Arixtra (GSK)
Molecular Formula: C31H43N3Na10O49S8
Molecular Weight: 1728.08
Percent Composition: C 21.55%, H 2.51%, N 2.43%, Na 13.30%, O 45.37%, S 14.84%
Literature References: Synthetic pentasaccharide corresponding to the antithrombin binding site of heparin, q.v. Prepn: M. Petitou et al., EP 84999; eidem, US 4818816 (1983, 1989 both to Choay); M. Petitou et al., Carbohydr. Res. 167, 67 (1987). Review of pharmacology: J. M. Herbert et al., Cardiovasc. Drug Rev. 15, 1-26 (1997). Clinical pharmacokinetics: B. Boneu et al., Thromb. Haemostasis 74, 1468 (1995). Clinical trial for prevention of post-operative deep-vein thrombosis: A. G. G. Turpie et al., N. Engl. J. Med. 344, 619 (2001). Clinical comparison with enoxaparin, q.v. in treatment of established deep-vein thrombosis: H. R. Büller et al., Ann. Intern. Med. 140, 867 (2004). Review of clinical safety and efficacy: A. G. G. Turpie, Expert Opin. Drug Saf. 4, 707-721 (2005).
Properties: White powder after lyophilisation. [a]D23 +48° (c = 0.61 in water).
Optical Rotation: [a]D23 +48° (c = 0.61 in water)
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic. |